Navigation Links
Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
Date:6/11/2013

Mississauga, ON (PRWEB) June 11, 2013

Therapure Biopharma Inc., a contract development and manufacturing organization (CDMO) of biotherapeutics, is pleased to announce the company will participate as a subcontractor for DynPort Vaccine Company LLC (DVC), a CSC company, that was awarded a US cost-plus-fixed-fee contract with a maximum value of $157.3 million (prime contract number W911QY-13-C-0056) by the US Department of Defense (DoD) to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.

Therapure’s subcontract under the above prime contract includes process optimization as well as manufacture of all clinical and nonclinical materials (drug product) to support DVC’s contract to develop, test and obtain the US Food and Drug Administration (FDA) approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents. Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women.”

Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. Department of Defense, Department of the Army, Chemical Biological Medical Systems Joint Project Management Office (CBMS JPMO), Medical Identification and Treatment Systems Joint Product Management Office (MITS JPMO).

ABOUT THERAPURE BIOPHARMA INC.
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a CDMO, Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop innovative and efficient solutions to advance client products from discovery to market. Therapure’s 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and is built to U.S. FDA, EMA, MHRA and Health Canada standards.

For more information, please visit: http://www.therapurebio.com.

Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
905-286-6270

Read the full story at http://www.prweb.com/releases/2013/6/prweb10824674.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. $9 million grant awarded to UH to study, treat learning disabilities
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
7. Southeast program to fight diabetes awarded nearly $10 million by HHS
8. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
9. 29 Johns Hopkins stem cell researchers awarded funding
10. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
11. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology: